Literature DB >> 12180819

Tolerance through bone marrow transplantation with costimulation blockade.

Thomas Wekerle1, Peter Blaha, Felix Langer, Maximilian Schmid, Ferdinand Muehlbacher.   

Abstract

The routine induction of tolerance in organ transplant recipients remains an unattained goal. The creation of a state of mixed chimerism through allogeneic bone marrow transplantation leads to robust donor-specific tolerance in several experimental models and this approach has several features making it attractive for clinical development. One of its major drawbacks, however, has been the toxicity of the required host conditioning. The use of costimulation blocking reagents (anti-CD 154 monoclonal antibodies and the fusion protein CTLA4Ig) has led to much less toxic models of mixed chimerism in which global T cell depletion of the host is no longer necessary and which has even allowed the elimination of all cytoreductive treatment when combined with the injection of very high doses of bone marrow cells. In this overview we will briefly discuss general features of tolerance induction through bone marrow transplantation, will then describe recent models using costimulation blockade to induce mixed chimerism and will review the mechanisms of tolerance found with these regimens. Finally we will attempt to identify issues related to the clinical introduction of bone marrow transplantation with costimulation blockade which remain unresolved.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12180819     DOI: 10.1016/s0966-3274(02)00016-3

Source DB:  PubMed          Journal:  Transpl Immunol        ISSN: 0966-3274            Impact factor:   1.708


  8 in total

1.  The role of natural killer T cells in costimulation blockade-based mixed chimerism.

Authors:  Patrick-Nikolaus Nierlich; Christoph Klaus; Sinda Bigenzahn; Nina Pilat; Zvonimir Koporc; Ines Pree; Ulrike Baranyi; Masaru Taniguchi; Ferdinand Muehlbacher; Thomas Wekerle
Journal:  Transpl Int       Date:  2010-11       Impact factor: 3.782

Review 2.  Transplantation tolerance through mixed chimerism.

Authors:  Nina Pilat; Thomas Wekerle
Journal:  Nat Rev Nephrol       Date:  2010-08-31       Impact factor: 28.314

Review 3.  Facilitating physiologic self-regeneration: a step beyond islet cell replacement.

Authors:  Pleunie P M Rood; Rita Bottino; A N Balamurugan; Yong Fan; David K C Cooper; Massimo Trucco
Journal:  Pharm Res       Date:  2006-01-01       Impact factor: 4.200

4.  Combining Treg therapy with mixed chimerism: Getting the best of both worlds.

Authors:  Nina Pilat; Thomas Wekerle
Journal:  Chimerism       Date:  2010 Jul-Sep

5.  Absence of inducible costimulator on alloreactive T cells reduces graft versus host disease and induces Th2 deviation.

Authors:  Vanessa M Hubbard; Jeffrey M Eng; Teresa Ramirez-Montagut; Kartono H Tjoe; Stephanie J Muriglan; Adam A Kochman; Theis H Terwey; Lucy M Willis; Rafaella Schiro; Glen Heller; George F Murphy; Chen Liu; Onder Alpdogan; Marcel R M van den Brink
Journal:  Blood       Date:  2005-06-14       Impact factor: 22.113

6.  Simultaneous administration of a low-dose mixture of donor bone marrow cells and splenocytes plus adenovirus containing the CTLA4Ig gene result in stable mixed chimerism and long-term survival of cardiac allograft in rats.

Authors:  Yongzhu Jin; Qingyin Zhang; Jie Hao; Xiang Gao; Yinglu Guo; Shusheng Xie
Journal:  Immunology       Date:  2003-10       Impact factor: 7.397

7.  Development and in vitro characterization of canine CD40-Ig.

Authors:  Christoph Jochum; Mechthild Beste; Diane Stone; Scott S Graves; Rainer Storb
Journal:  Vet Immunol Immunopathol       Date:  2008-02-16       Impact factor: 2.046

8.  Dipeptidyl peptidase IV (DPPIV/CD26) inhibition does not improve engraftment of unfractionated syngeneic or allogeneic bone marrow after nonmyeloablative conditioning.

Authors:  Elisabeth Schwaiger; Christoph Klaus; Veerle Matheeussen; Ulrike Baranyi; Nina Pilat; Haley Ramsey; Stephan Korom; Ingrid De Meester; Thomas Wekerle
Journal:  Exp Hematol       Date:  2011-11-13       Impact factor: 3.084

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.